Journal
BIOLOGY OF THE CELL
Volume 115, Issue 1, Pages -Publisher
WILEY
DOI: 10.1111/boc.202200037
Keywords
ADPKD; apoptosis; autophagy; cell growth; RG7112
Categories
Ask authors/readers for more resources
This study reveals that inhibition of mTOR activates autophagy in ADPKD cells, leading to drug degradation through autophagic vesicles and reduced therapeutic efficacy. The combination of mTOR inhibitor and autophagy inhibitor enhances the decrease in cell proliferation caused by mTOR inhibition. Targeting MDM2, a downstream effector of mTOR signaling, prevents TP53 degradation and induces cell apoptosis, providing a new therapeutic option for ADPKD treatment.
Introduction Autosomal dominant polycystic kidney disease (ADPKD) is characterised by progressive cysts formation and renal enlargement that in most of cases leads to end stage of renal disease (ESRD). This pathology is caused by mutations of either PKD1 or PKD2 genes that encode for polycystin-1 (PC1) and polycystin-2 (PC2), respectively. These proteins function as receptor-channel complex able to regulate calcium homeostasis. PKD1/2 loss of function impairs different signalling pathways including cAMP and mTOR that are considered therapeutic targets for this disease. In fact, Tolvaptan, a vasopressin-2 antagonist that reduces cAMP levels, is the only drug approved for ADPKD treatment. Nevertheless, some ADPKD patients developed side effects in response to Tolvaptan including liver damage. Conversely, mTOR inhibitors that induced disease regression in ADPKD animal models failed the clinical trials. Results Here, we show that the inhibition of mTOR causes the activation of autophagy in ADPKD cells that could reduce therapy effectiveness by drug degradation through the autophagic vesicles. Consistently, the combined treatment with rapamycin and chloroquine, an autophagy inhibitor, potentiates the decrease of cell proliferation induced by rapamycin. To overcome the dangerous activation of autophagy by mTOR inhibition, we targeted MDM2 (a downstream effector of mTOR signalling) that is involved in TP53 degradation by using RG7112, a small-molecule MDM2 inhibitor used for the treatment of haematologic malignancies. The inhibition of MDM2 by RG7112 prevents TP53 degradation and increases p21 expression leading to the decrease of cell proliferation and the activation of apoptosis. Conclusion The targeting of MDM2 by RG7112 might represent a new therapeutic option for the treatment of ADPKD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available